New York - US-based pharmaceutical major Moderna's experimental vaccine, mRNA-1273, designed to protect against Covid-19 virus, was generally well tolerated and prompted neutralising antibody activity in healthy adults, say researchers.
In the Phase 1 trial, led by Lisa A Jackson of Kaiser Permanente Washington Health Research Institute in Seattle, the 45 participants ages 18 to 55 years received the candidate vaccine. The results from the first stage of Moderna's vaccine trial showed the first 45 participants developed antibodies to the virus.The interim analysis included results of tests measuring levels of vaccine-induced neutralising activity through day 43 after the second injection.
However, more than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'We're pleased': Results show Moderna Covid-19 vaccine is safe, induces immune responseExperts say a vaccine is needed to put an end to the coronavirus pandemic that has sickened millions and caused nearly 575,000 deaths worldwide.
Source: TimesLIVE - 🏆 28. / 59 Read more »
Moderna Covid-19 vaccine produces antibodies in all patients testedThe shares rise more than 16% in after-hours trading on the news
Source: BDliveSA - 🏆 12. / 63 Read more »
SA's first Covid-19 vaccine trial brings hopeThe AU-commissioned programme intends to have injection by first quarter of next year.
Source: IOL - 🏆 46. / 51 Read more »